Dose regimen for administration of LAG-3/PD-L1 bispecific antibodies

Dose regimen for administration of LAG-3/PD-L1 bispecific antibodies

The present application relates to dosage regimens for the administration of antibody molecules that bind programmed death-ligand 1 (PD-L1) and lymphocyte activation gene 3 (LAG-3) and their medical use in the treatment of cancer in human patients. 本申请涉及用于结合程序性死亡-配体1(PD-L1)和淋巴细胞活化基因3(LAG-3)的抗体分子的施用的...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: GLIDDEN DANIEL, HOLTZ JOSEPHINE-BEATE, CATALIER, LOUIS, GRADINARU CRISTIAN, MOREAU MICHEL, ZIEMASCZEWSKI, FIONA, SHEPHERD CHRISTOPHER, LIANG JIANMEI
Format: Patent
Sprache:chi ; eng
Schlagworte:
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The present application relates to dosage regimens for the administration of antibody molecules that bind programmed death-ligand 1 (PD-L1) and lymphocyte activation gene 3 (LAG-3) and their medical use in the treatment of cancer in human patients. 本申请涉及用于结合程序性死亡-配体1(PD-L1)和淋巴细胞活化基因3(LAG-3)的抗体分子的施用的剂量方案及它们在人类患者癌症的治疗中的医学用途。